Does insurance cover weight loss medication? Commercial plans, Medicare and Medicaid in 2026
Some plans cover weight loss medication with prior authorization, some exclude it, and Medicare gained new exceptions in 2026. Here is how coverage works and how to find out what your plan does.
Sometimes, and it depends heavily on which plan you have. Many commercial plans cover weight loss medication only with prior authorization, some exclude it entirely, and Medicare has long been barred from covering drugs used purely for weight loss. In 2026 that last rule gained some important exceptions, which is why the answer has become more complicated and, for some people, better.
The short version
- Commercial coverage is set plan by plan, often by the employer. The same insurer can cover Wegovy or Zepbound for one employer's staff and exclude it for another's.
- Most plans that do cover these drugs require prior authorization, usually showing your BMI, any weight-related conditions and prior lifestyle efforts.
- Medicare Part D can cover Wegovy for reducing cardiovascular risk in people with established heart disease, and Zepbound for moderate to severe obstructive sleep apnea with obesity, because those are FDA-approved uses beyond weight loss.
- A temporary CMS program, the Medicare GLP-1 Bridge, began July 1, 2026, offering certain weight-management drugs for a $50 monthly copay to eligible beneficiaries. It is scheduled to run through December 31, 2027.
- Medicaid coverage varies by state, and California and Michigan both narrowed coverage on January 1, 2026.
Coverage rules in this area have shifted several times since 2024 and will shift again. Everything below reflects what we could verify as of October 2026. Before you rely on any of it, call your plan or check its formulary, and expect the details to change.
Commercial insurance
Employer and individual plans decide for themselves whether to cover anti-obesity medications. Some cover them as a standard benefit. Others treat them as an optional add-on the employer can buy or decline, and some employers that added coverage in 2023 or 2024 later dropped it because of cost. Pharmacy benefit managers also choose preferred drugs, so a plan may cover one GLP-1 for weight management but not another.
How to find out what your plan covers
- Look up the plan's drug formulary, often on the insurer's website, and search for Wegovy, Zepbound and Foundayo by name.
- Note the tier and any letters next to the drug, such as PA (prior authorization), ST (step therapy) or QL (quantity limit).
- Call the member services number on your card and ask directly: "Does my plan cover medications for chronic weight management, and what are the criteria?"
- If you get coverage through work, your HR or benefits team can tell you whether the employer opted in.
What prior authorization usually asks for
Criteria vary, but a prior authorization request for a weight-management GLP-1 typically includes:
- Your BMI, usually 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or sleep apnea.
- Documentation of the conditions themselves.
- Evidence of a lifestyle program or prior attempts at weight loss, sometimes for a defined period.
- For continued coverage, proof of a response after a few months, commonly at least 5% weight loss.
Denials are common on first submission and are not always the final word. A clinician can appeal with additional documentation, and you have rights to an internal appeal and, in many cases, an external review.
Medicare
The Medicare Part D statute excludes drugs used for weight loss. For years that meant Medicare could not cover Wegovy or Zepbound when prescribed for obesity alone. Two developments have changed that picture.
Coverage for other FDA-approved uses
When the FDA approves a weight-management drug for a separate medical condition, Part D plans can cover it for that condition. Two such approvals matter here:
- Wegovy and cardiovascular risk. In March 2024 the FDA approved Wegovy to reduce the risk of heart attack, stroke and cardiovascular death in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial (NEJM, 2023). CMS then confirmed that Part D plans may cover it for this use.
- Zepbound and obstructive sleep apnea. In December 2024 the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials. CMS confirmed in early 2025 that Part D plans may cover it for this use.
Plans are allowed to cover these uses, not required to put them on every formulary, and most use prior authorization to confirm the diagnosis. For sleep apnea, that usually means a sleep study showing moderate to severe disease.
The Medicare GLP-1 Bridge
CMS launched a temporary program in July 2026 that lets eligible Part D and Medicare Advantage enrollees get certain weight-management drugs for a flat $50 monthly copay. According to the National Council on Aging's summary of CMS materials (August 2026), covered drugs include Wegovy (injection and pill), the Zepbound KwikPen and Foundayo. Eligibility requires one of these combinations:
- BMI of 35 or higher.
- BMI of 30 or higher with heart failure, uncontrolled hypertension or kidney disease.
- BMI of 27 or higher with prior stroke, prior heart attack, prediabetes or peripheral artery disease.
Your prescriber has to submit a prior authorization to a central CMS processing center, including confirmation that you have received lifestyle counseling. The $50 copay does not count toward your Part D deductible or out-of-pocket limit. CMS extended the Bridge through December 31, 2027, and paused the Medicare portion of a separate longer-term model, so what happens after 2027 has not been decided. Details are at Medicare.gov or 1-800-MEDICARE.
Worth knowing
Manufacturer copay cards cannot be used with Medicare, Medicaid or other government insurance. If you are on Medicare and paying cash outside your plan, the manufacturer self-pay programs are a separate option, covered in our article on GLP-1 costs without insurance.
Medicaid
Each state decides whether its Medicaid program covers drugs for weight management. Several states cut back at the start of 2026:
- California: Medi-Cal stopped covering GLP-1s prescribed for weight loss for adults 21 and older as of January 1, 2026. Coverage for diabetes and cardiovascular indications continues.
- Michigan: Michigan Medicaid, including the Healthy Michigan Plan, began limiting coverage of GLP-1s for obesity on January 1, 2026, with stricter criteria. Reports describe the threshold differently, so check the current policy with your plan.
- Illinois: We found conflicting information about Illinois Medicaid coverage for weight management. Check with Illinois HFS or your managed care plan directly.
Medicaid and state rules change often; verify with your state agency or plan before assuming coverage either way.
Diabetes is a different question
Ozempic and Mounjaro are approved for type 2 diabetes, and most plans, including Medicare and Medicaid, cover them for that diagnosis. They should not be prescribed for diabetes as a way to get weight-loss coverage when you don't have diabetes, and many plans now check for a diabetes diagnosis before paying.
If your plan says no
Ask for the denial in writing and the specific reason. Ask your clinician whether an appeal makes sense. If coverage is excluded entirely, self-pay programs and HSA or FSA funds may help; see our guide to HSA and FSA use. If cost is pushing you toward a cheaper compounded product, read our article on compounded GLP-1s first.
A clinician can tell you which criteria you meet and document them properly for a prior authorization. Our weight management page explains how we handle evaluations, though no practice can promise that an insurer will approve a claim.
Questions patients ask us
Does Medicare cover Wegovy for weight loss?
Historically, Part D could not cover drugs used only for weight loss. As of October 2026, Part D plans may cover Wegovy for cardiovascular risk reduction in people with established heart disease, and a temporary CMS program called the Medicare GLP-1 Bridge offers Wegovy and some other drugs for a $50 monthly copay to eligible beneficiaries through December 31, 2027.
Who qualifies for the Medicare GLP-1 Bridge?
According to the National Council on Aging's summary of CMS materials, you need Part D or Medicare Advantage drug coverage and one of these: a BMI of 35 or higher; a BMI of 30 or higher with heart failure, uncontrolled hypertension or kidney disease; or a BMI of 27 or higher with prior stroke, prior heart attack, prediabetes or peripheral artery disease. Prior authorization is required.
Does Medicare cover Zepbound for sleep apnea?
Medicare Part D plans may cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, an FDA-approved use since December 2024. CMS confirmed this in early 2025. Plans decide whether to include it and usually require prior authorization, often including a sleep study showing the severity.
Why does my employer plan not cover Wegovy or Zepbound?
Many employer plans treat weight-management drugs as an optional benefit, and some employers decline it or drop it because of cost. Pharmacy benefit managers also choose preferred drugs, so one GLP-1 may be covered and another not. Your HR or benefits team can tell you whether your employer opted in.
What does prior authorization for a GLP-1 usually require?
Typically your BMI, documentation of weight-related conditions such as high blood pressure or diabetes, and evidence of lifestyle efforts or a program. Continued coverage often requires showing a response, commonly at least 5% weight loss after a few months. Exact criteria vary by plan, so ask for them in writing.
Can I appeal if insurance denies my GLP-1?
Yes. Ask for the denial and the specific reason in writing. Your clinician can submit an appeal with more documentation, such as lab results or records of related conditions. If the internal appeal fails, many plans allow an external review. If the drug is excluded from your plan entirely, appeals are less likely to succeed.
Does Medi-Cal cover GLP-1s for weight loss?
Medi-Cal stopped covering GLP-1 medications prescribed for weight loss for members 21 and older as of January 1, 2026. Coverage continues for diabetes and certain cardiovascular uses. Check with Medi-Cal or your managed care plan for current rules, since state Medicaid policies change often.
Does Michigan Medicaid cover weight loss medication?
Michigan Medicaid, including the Healthy Michigan Plan, began limiting coverage of GLP-1s for obesity on January 1, 2026, with stricter criteria than before. Reports describe the new threshold differently, so confirm the current policy with your Medicaid health plan or the Michigan Department of Health and Human Services.
Can I use a manufacturer savings card with Medicare?
No. Federal rules bar manufacturer copay cards for people using Medicare, Medicaid or other government insurance to pay for the drug. Medicare beneficiaries can instead check the GLP-1 Bridge or pay cash through a manufacturer self-pay program outside their plan, which will not count toward Part D spending.
Can I get Ozempic covered instead if Wegovy is not covered?
Only if you have type 2 diabetes. Ozempic and Mounjaro are approved for type 2 diabetes, and plans cover them on that basis. Prescribing them for weight loss without diabetes to get coverage is not appropriate, and many plans check for a diabetes diagnosis before paying.
Talk to a licensed clinician
Reading about a treatment is not the same as knowing whether it fits your history. A consultation is a conversation about your own situation — not a sales call, and not a promise of any outcome.
